Aryal Bibek, Yamakuchi Munekazu, Shimizu Toshiaki, Kadono Jun, Furoi Akira, Gejima Kentaro, Komokata Teruo, Koriyama Chihaya, Hashiguchi Teruto, Imoto Yutaka
Cardiovascular and Gastroenterological Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan.
Department of Laboratory and Vascular Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan.
J Oncol. 2019 Jan 6;2019:1925315. doi: 10.1155/2019/1925315. eCollection 2019.
Platelet derived growth factor-BB (PDGF-BB) has emerged as one of the key cytokines in malignant transformation of different cells. PDGF-BB also exhibits a potent mitogenic effect on liver cells; studies have advocated clinical implications of monitoring serum PDGF-BB (sPDGF-BB) in patients with liver disease. We thus investigated the predictive relevance of perioperative sPDGF-BB after curative resection of hepatocellular carcinoma (HCC).
We evaluated perioperative sPDGF-BB in a prospective homogenous cohort of 40 patients diagnosed with HCC. During the first two-year follow-up, patients were evaluated every three months for postresection HCC recurrence.
Patients who developed recurrence during two-year follow-up were found to have lower concentration of sPDGF-BB than those without recurrence in both pre- and postoperative settings ( < 0.05 and < 0.001, resp.). We validated that the reduced postoperative sPDGF-BB (< 2133.29 pg/mL) was associated with an increased incidence of postresection HCC recurrence [area under curve (AUC) > 0.8, 95% confidence interval (CI) = 0.68 - 0.94, < 0.001]; furthermore, we were able to demonstrate that postoperative sPDGF-BB was an independent predictor of HCC recurrence (hazard ratio = 5.64, 95% CI = 1.56 - 20.30, < 0.01).
These findings provide a new insight into an association between diminished perioperative sPDGF-BB and HCC recurrence. Patients with low perioperative sPDGF-BB progressed early HCC recurrence. Therefore, evaluating perioperative sPDGF-BB may provide useful clinical information to characterize patients with postresection HCC recurrence.
血小板衍生生长因子-BB（PDGF-BB）已成为不同细胞恶性转化的关键细胞因子之一。PDGF-BB对肝细胞也具有强大的促有丝分裂作用；研究提倡监测肝病患者血清PDGF-BB（sPDGF-BB）的临床意义。因此，我们研究了肝细胞癌（HCC）根治性切除术后围手术期sPDGF-BB的预测相关性。
我们在一个前瞻性同质队列中评估了40例诊断为HCC患者的围手术期sPDGF-BB。在最初的两年随访期间，每三个月对患者进行一次评估，以检测切除术后HCC复发情况。
在两年随访期间出现复发的患者，术前和术后sPDGF-BB浓度均低于未复发患者（分别为P<0.05和P<0.001）。我们验证了术后sPDGF-BB降低（<2133.29 pg/mL）与切除术后HCC复发发生率增加相关[曲线下面积（AUC）>0.8，95%置信区间（CI）=0.68-0.94，P<0.001]；此外，我们能够证明术后sPDGF-BB是HCC复发的独立预测因子（风险比=5.64，95%CI=1.56-20.30），P<0.01）。
这些发现为围手术期sPDGF-BB降低与HCC复发之间的关联提供了新的见解。围手术期sPDGF-BB低的患者HCC复发较早。因此，评估围手术期sPDGF-BB可能为表征切除术后HCC复发患者提供有用的临床信息。
